drugset / Trial / NCT02465866

A Four-Period, Four-Treatment, Four-Way Relative Bioavailability Study of CL-108 Under Fed and Fasted Conditions

NCT02465866

Phase 1 Completed 20 enrolled Charleston Laboratories, Inc
RandomizedCrossoverOpen-labelBasic science

Summary

This study will compare the relative bioavailability of hydrocodone, acetaminophen, and promethazine in CL-108 (hydrocodone 7.5mg/ acetaminophen 325 mg/ promethazine 12.5 mg) manufactured by Charleston Laboratories, Inc. to hydrocodone in Vicoprofen (hydrocodone 7.5 mg /ibuprofen 200 mg), promethazine 12.5 mg, and acetaminophen in Ultracet (tramadol HCl 37.5 mg/acetaminophen 325 mg) under fasted and fed conditions.

Timeline

Start
2014-11
Primary completion
2015-04
Completion
2015-04

Drugs

EvaluationDrugModalityDoseRoute
Subject CL-108 Unknown 7.5 mg Oral
Subject CL-108 Unknown 12.5 mg Oral
Subject CL-108 Unknown 325 mg Oral
Comparator Promethazine Small molecule 12.5 mg Oral
Comparator Ultracet Unknown 37.5 mg Oral
Comparator Ultracet Unknown 325 mg Oral
Comparator Vicoprofen Unknown 7.5 mg Oral
Comparator Vicoprofen Unknown 200 mg Oral

Indications

No indication recorded.